COVID19
Conditions
Brief summary
This study is a continuation study of the original V-01-I phase trial, using a single-center, single-arm, open design to evaluate the immunogenicity and safety of the third dose booster immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in healthy participants immunized with two doses schedule of V-01. The primary objective is to evaluate the Immunogenicity of the third dose booster immunization of V-01 in healthy participants immunized with two doses schedule of V-01. The secondary objective is to evaluate the safety of the third dose booster immunization of V-01 in healthy participants immunized with two doses schedule of V-01.
Detailed description
The plan is to booster immunize the participants previously in 10μg test group in V-01 clinical trial phase I, 48 participants are planned to be enrolled. The actual case number will be calculated by the participants who signed the ICF and got actual inoculation with the third dose. Vaccination and follow-up: Three to six months after the two doses of V-01 (10 μg) were vaccinated, the participants received a booster dose of investigational vaccine (V-01, 10 μg) at the deltoid muscle of the upper arm. Perform safety and immunogenicity related inspections in accordance with the schedule in the plan.
Interventions
The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Sponsors
Guangdong Center for Disease Prevention and Control
Simoon Record Pharma Information Consulting Co., Ltd.
Livzon Pharmaceutical Group Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntarily participate in the study and sign the informed consent form * The participants who were enrolled in the 10 μg test group in the previous study titled A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants, and went through the full course immunization without meeting the exclusive criteria. * No history of contact with confirmed, asymptomatic or suspected COVID-19 cases. * Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 6 months after vaccination; females of childbearing age refer to premenopausal women and women within 2 years after menopause.
Exclusion criteria
* Innoculated with COVID-19 vaccines other than V-01; * History of high fever (axillary temperature ≥ 39℃) and last for more than 3 days, or serious allergic reactions during the last immunization with V-01; * History of obvious allergic reactions or allergic reactions that needed to be medical intervention during the last immunization with V-01; * After two doses of V-01 inoculation, a newly diagnosed severe chronic disease or the original chronic disease is poorly controlled by drugs (applicable to ≥60 years old): history of chronic respiratory diseases (including moderate to severe asthma, COPD, pulmonary fibrosis) , Hypertension which can not be controlled by drugs (systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg), history of severe cardiovascular disease (including heart failure, coronary artery disease, cardiomyopathy), history of chronic kidney disease, history of cancer, diabetes (blood sugar) Unsatisfactory control or serious complications related to diabetes); * Any confirmed or suspected immunosuppressive or immunodeficiency disorder, including HIV infection and asplenia; recurrent severe infections and administration of immunosuppressive drugs during the past 6 months, excluding topical steroids or short-term oral steroids (\<14 days); * Having received immunoglobulin and/or any blood products 3 months prior to the investigational vaccine dose; * Other scenarios that may be medically, psychologically or socially contradicted with the trial protocol at the investigator's discretion or preclude informed consents of the participants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity Endpoints | 14 days after booster immunization | 1. The seroconvension, GMT, and GMI of SARS-CoV-2 neutralizing antibodies (live virus, pseudovirus neutralizing test method) 2. The seroconvension, GMT, and GMI of SARS-CoV-2 RBD antibodies (Enzyme-linked Immuno Sorbent Assay，ELISA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety Endpoints | Day 0-7 after booster immunization, 6 months after booster immunization | 1. The occurrence of AEs at each time point (at least 30 minutes, 0-7 days, and within 30 days after booster vaccination); 2. The incidence of serious adverse events (SAE) (within 6 months after booster vaccination). |
Countries
China
Outcome results
None listed